Stockscreener 앱 받기
32.39
2.12%
-0.70
전일 마감가:
$33.09
열려 있는:
$33.33
하루 거래량:
1.11M
Relative Volume:
0.94
시가총액:
$1.85B
수익:
$199.89M
순이익/손실:
$52.48M
주가수익비율:
38.11
EPS:
0.85
순현금흐름:
$61.15M
1주 성능:
+4.92%
1개월 성능:
+28.89%
6개월 성능:
+174.03%
1년 성능:
+162.91%
1일 변동 폭
$32.26
$33.77
1주일 범위
$30.17
$35.40
52주 변동 폭
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
32.39 | 1.89B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
(STOK) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Stoke Therapeutics: A Deep Dive into Clinical Progress and Market Sentiment - AD HOC NEWS
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - AOL.com
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat
Insider Selling Alert: Kaye Edward M. MD Sells Shares of Stoke T - GuruFocus
Stoke Therapeutics Insider Sold Shares Worth $433,385, According to a Recent SEC Filing - marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4%Time to Buy? - MarketBeat
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1%What's Next? - MarketBeat
Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Stoke Therapeutics, Inc. $STOK Shares Purchased by Franklin Resources Inc. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $267,723.36 in Stock - MarketBeat
Jonathan Allan Sells 8,785 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 6,453 Shares - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 1,018 Shares of Stock - MarketBeat
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance
Allan Jonathan of Stoke Therapeutics sells $306k in shares By Investing.com - Investing.com South Africa
Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k - Investing.com India
Allan Jonathan of Stoke Therapeutics sells $306k in shares - Investing.com
Stoke Therapeutics Executives Conduct Multiple Stock Sales - TradingView — Track All Markets
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Fly 36% But Investors Aren't Buying For Growth - 富途牛牛
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Zorevunersen shows promise for Dravet syndrome in long-term data By Investing.com - Investing.com South Africa
Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting - TipRanks
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke Therapeutics, Inc. and Biogen Present Data on Zorevunersen at AES 2025 - TradingView — Track All Markets
Biogen and Stoke Therapeutics Present Promising Long-term Data for Zorevunersen in Treating Dravet Syndrome at AES 2025 - Quiver Quantitative
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - The Manila Times
Biogen (Nasdaq: BIIB) and Stoke share long-term Dravet data on zorevunersen - Stock Titan
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry - simplywall.st
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 1,066 Shares - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Insider Sells 2,006 Shares of Stock - MarketBeat
Stoke Therapeutics: A Long-Term Biotech Growth PlayWhy I Assign A Hold Rating (STOK) - Seeking Alpha
Geode Capital Management LLC Has $11.04 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 2,292 Shares of Stock - MarketBeat
Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541 By Investing.com - Investing.com South Africa
Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541 - Investing.com Nigeria
Can Stoke Therapeutics Inc. stock beat analyst upgradesJuly 2025 Sector Moves & Risk Managed Trade Strategies - Newser
Does Stoke Therapeutics Still Make Sense After Its 2025 Rally And Lofty Valuation Multiples? - simplywall.st
A Look at Stoke Therapeutics (STOK) Valuation After a 167% Year-to-Date Surge - Yahoo Finance
Price-Driven Insight from (STOK) for Rule-Based Strategy - news.stocktradersdaily.com
Biogen and Stoke Therapeutics Present Promising Zorevunersen Data for Dravet Syndrome at 2025 American Epilepsy Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Biogen
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Business Wire
Advantage Alpha Capital Partners LP Purchases Shares of 17,888 Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):